Resveratrol inhibits firefly luciferase

被引:61
|
作者
Bakhtiarova, Adel [1 ]
Taslimi, Paul [1 ]
Elliman, Stephen J. [1 ]
Kosinski, Penelope A. [1 ]
Hubbard, Brian [1 ]
Kavana, Michael [1 ]
Kemp, Daniel M. [1 ]
机构
[1] Novartis Inst BioMed Res, Diabet & Metab Dis Area, Cambridge, MA 02139 USA
关键词
resveratrol; firefly luciferase; SirT1; therapeutic; drug; cancer; neurodegeneration;
D O I
10.1016/j.bbrc.2006.10.057
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The potential therapeutic value of resveratrol in age-related disease settings including cancer, diabetes, and Alzheimer's has emerged from a rapidly growing body of experimental evidence. Protection from oxidative stress appears to be a common feature of resveratrol that may be mediated through SirT1, though more specific molecular mechanisms by which resveratrol mediates its effects remain unclear. This has prompted an upsurge in cell-based mechanistic studies, often incorporating reporter assays for pathway elucidation in response to resveratrol treatment. Here, we report that resveratrol potently inhibits firefly lucifierase with a K-i value of 2 mu M, and caution that this confounding element may lead to compromised data interpretation. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 50 条